Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucagon, Other

Zealand Restructures Business to Focus on R&D and Cuts 90% of US Workforce; Samsung and JDRF T1DM Invest in Jaguar Gene Therapy

Here is a brief preview of this blast: Two cardiometabolic-related news items have been observed: Zealand announced a company restructuring comprised of a shift back toward an R&D organization, a CEO transition, and a 90% US workforce reduction (listen to call investor call here); and Jaguar Gene Therapy announced Samsung Ventures and the JDRF T1D Fund have invested in the company. Below, FENIX provides highlights and insights for the respective new items. 

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.